TP-β Antagonist Therapy for Bladder Cancer Treatment

The patent applies parameter changes by identifying TP-β expression levels as a key parameter that distinguishes responsive from non-responsive tumors. By measuring TP-β expression (a molecular parameter) and using it to guide treatment selection, the patent transforms conventional cancer therapy into a targeted approach. This parameter-based stratification enables clinicians to select appropriate TP-β antagonists for patients whose tumors overexpress TP-β, thereby improving treatment effectiveness while providing a tailored therapeutic option.

The patent implements preliminary action by requiring TP-β expression assessment to be performed before administering TP-β antagonist therapy. This pre-treatment molecular characterization ensures that only patients whose tumors exhibit elevated TP-β expression receive the targeted therapy. The preliminary diagnostic step prevents unnecessary treatment of patients with low TP-β expression, thereby improving treatment efficacy while maintaining a relatively simple protocol that adds only one initial testing step.

The patent applies segmentation by dividing cancer treatment into distinct phases and components: (1) molecular characterization phase to assess TP-β expression, (2) targeted therapy phase using TP-β antagonists for TP-β positive tumors, and (3) combination therapy phase integrating TP-β antagonists with conventional chemotherapies or radiation for enhanced efficacy. This segmented approach allows clinicians to start with the simpler targeted therapy for eligible patients and progress to more complex combination regimens only when necessary, thereby improving outcomes while managing treatment complexity in a structured manner.